Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleMotley Fool
Why Iovance Biotherapeutics Stock Was on Fire Today
View original at fool.comMotley Fool - Stock Analysis Title: Why Iovance Biotherapeutics Stock Was on Fire Today Date: 2026-09-24 23:57 Source: https://www.fool.com/investing/2026/09/24/why-iovance-biotherapeutics-stock-was-on-fire-toda/?source=iedfolrf0000001 <p>A new, bullish analyst take on <strong>Iovance Biotherapeutics</strong> <span cla…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Rated Iovance Biotherapeutics equity a buy with a price target of $15 per share upon resuming coverage of the stock.
60% confidence
Cited in these Via News reports
- Micron's Capex Doubled in a Year While Cash Hit $25 Billion: The Checkable Core of the AI Memory Boom →
- Palantir's AI Partnership Run Meets a 7% Tech Selloff, While Defense Stocks Sour →
- Palantir's AI platform keeps winning partners and upgrades, even as defense analysts turn gloomy and the stock slides →
